Combination Trial of BMS-690514 in Combination With FOLFIRI and FOLFOX
The purpose of this research study is to determine the highest dose of BMS-690514 that can be safely given in combination with the chemotherapeutic regimens (FOLFIRI and FOLFOX) to patients with advanced cancer
Cancer
DRUG: BMS-690514 / FOLFIRI|DRUG: BMS-690514 / FOLFOX
Safety assessment, throughout the study|dose-limiting toxicity (DLT), assessed for individual patients from C1D1 to C1D28 during the dose escalation portion of the protocol, until maximum tolerated dose is identified|determination of maximum tolerated dose (MTD), during dose escalation portion of the protocol. Three to six subjects are treated at a specified dose level. If deemed safe dose escalation continues until the maximum tolerated dose is identified
Describe anti-tumor of combination therapy, Every 8 weeks throughout the study|Describe effects of combination therapy on markers of therapeutic activity. e.g. blood, plasma and biopsy samples, throughtout the study
The purpose of this research study is to determine the highest dose of BMS-690514 that can be safely given in combination with the chemotherapeutic regimens (FOLFIRI and FOLFOX) to patients with advanced cancer